The EU-X-CT Recommendations on Cross-Border Access to Clinical Trials have been published this week, following collaboration among over 100 experts from patient organisations, academia, regulatory bodies, and industry.

Coordinated by EFGCP and EFPIA, the recommendations aim to enhance access to clinical trials for participants across European borders. Covering legal and ethical considerations, site readiness, and patient support, the guidance offers practical insights for all involved in cross-border trials.

Join us at the EU-X-CT Stakeholder Conference on 24 June 2025 to further explore these topics. 

The IHI Call 11 was officially launched on 17 June. EFPIA is proud to support this new call that brings public and private sectors together to address some of the most pressing health challenges.

Get details of the topics and how to apply here. Deadline for short proposals: 9 October 2025

In today’s evolving health research landscape, public private collaboration is key to driving impactful innovation. They deliver results to optimise the R&D processes, healthcare delivery and regulatory practice. 

The following articles describe the value that the Innovative Medicines Initiative (IMI) and Innovative Health Initiative (IHI) have for research foundations, and showcase how IMI and IHI are shaping the future of translational safety and enhance regulatory engagement.

Collectively, they underscore a shared vision: that well-structured partnerships can accelerate scientific progress, improve patient outcomes, and foster more resilient, responsive healthcare systems.